Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial

BACKGROUND: We assessed the efficacy of adding intraperitoneal (IP) chemotherapy to standard first-line intravenous (IV) chemotherapy in epithelial ovarian cancer (EOC) patients. METHODS: Patients with stage IIIC-IV EOC who underwent optimal debulking surgery were randomly assigned to four cycles of...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Tingyan, Jiang, Rong, Yu, Jinjin, Yang, Huijuan, Tu, Dongsheng, Dai, Zhiyuan, Shen, Yang, Zhang, Yuqin, Cheng, Xi, Jia, Huixun, Tu, Ruiqin, Wang, Huaying, Tang, Jie, Luan, Yuting, Cai, Shumo, Zang, Rongyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035193/
https://www.ncbi.nlm.nih.gov/pubmed/29899395
http://dx.doi.org/10.1038/s41416-018-0036-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035193/
https://www.ncbi.nlm.nih.gov/pubmed/29899395
http://dx.doi.org/10.1038/s41416-018-0036-7

Ejemplares similares